8.91

1.87% -0.17

After Hours: 9.11 0.20 +2.24%

Avalo Therapeutics Inc (AVTX)

Overview News Price History Financials Why AVTX Down? Discussions Forecast Stock Split

Avalo Therapeutics Inc stock is traded at $8.91, with a volume of 858.09K. It is down -1.87% in the last 24 hours and down -18.26% over the past month. Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Previous Close:

$9.08

Open:

$9.1

24h Volume:

858.09K

Relative Volume:

12.38

Market Cap:

$93.23M

Revenue:

$1.93M

Net Income/Loss:

$-7.96M

P/E Ratio:

-4.1636

EPS:

-2.14

Net Cash Flow:

$-36.78M

1W Performance:

-3.47%

1M Performance:

-18.26%

6M Performance:

-32.81%

1Y Performance:

+20,621%

1-Day Range:

$8.67

$9.81

1-Week Range:

$8.67

$9.99

52-Week Range:

$0.044

$34.46

Avalo Therapeutics Inc Stock (AVTX) Company Profile

Name

Avalo Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

410-522-8707

Address

540 GAITHER ROAD, ROCKVILLE

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

AVTX's Discussions on Twitter

Compare AVTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVTX Avalo Therapeutics Inc	8.91	93.23M	1.93M	-7.96M	-36.78M	-3,530.82
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-24	Initiated	BTIG Research	Buy
Oct-24-24	Initiated	H.C. Wainwright	Neutral
Apr-16-24	Upgrade	Oppenheimer	Perform → Outperform
Sep-24-21	Initiated	RBC Capital Mkts	Outperform

Avalo Therapeutics Inc Stock (AVTX) Latest News

Dec 21, 2024

BTIG Research Begins Coverage on Avalo Therapeutics (NASDAQ:AVTX) - Defense World

Dec 21, 2024

Dec 20, 2024

Avalo Therapeutics initiated with a Buy at BTIG - Yahoo Finance

Dec 20, 2024

Dec 19, 2024

BTIG optimistic on Avalo Therapeutics stock with potential for transformative Phase 2b trial results - Investing.com Canada

Dec 19, 2024

(AVTX) Trading Report - Stock Traders Daily

Dec 19, 2024

Dec 17, 2024

LUCID CAPITAL MARKETS Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation - MSN

Dec 17, 2024

Dec 12, 2024

Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Drops By 46.9% - MarketBeat

Dec 12, 2024

Dec 09, 2024

Avalo Therapeutics (AVTX) Is a Potential Hidden Gem with Significant Risk - TipRanks

Dec 09, 2024

Dec 08, 2024

Trading (AVTX) With Integrated Risk Controls - Stock Traders Daily

Dec 08, 2024

Dec 05, 2024

RA Capital Management L.P. Takes Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - MarketBeat

Dec 05, 2024

Nov 27, 2024

Learn to Evaluate (AVTX) using the Charts - Stock Traders Daily

Nov 27, 2024

Nov 21, 2024

Avalo Therapeutics (FRA:C6K0) Cash From Other Investing Act - GuruFocus.com

Nov 21, 2024

Avalo Therapeutics (FRA:C6K0) Cyclically Adjusted PS Ratio : 0.02 (As of Nov. 21, 2024) - GuruFocus.com

Nov 21, 2024

Nov 20, 2024

REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday - MSN

Nov 20, 2024

Nov 17, 2024

(AVTX) Investment Analysis and Advice - Stock Traders Daily

Nov 17, 2024

Nov 15, 2024

Orbimed Advisors LLC Acquires New Stake in Avalo Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Avalo Therapeutics director June Almenoff acquires $12,749 in stock - Investing.com

Nov 14, 2024